Non–High-Density Lipoprotein Cholesterol and Its Correlation With Anthropometric Markers of Cardiovascular Risk in Hemodialysis

2012 ◽  
Vol 22 (2) ◽  
pp. 251-257 ◽  
Author(s):  
Claudia Maria Costa de Oliveira ◽  
Suelen Rios Melo ◽  
Aline Moreira do Vale Mota ◽  
Marcos Kubrusly
Keyword(s):  
Cardiovascular Risk ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Anthropometric Markers

High-density Lipoprotein Cholesterol: Current Perspective for Clinicians

Angiology ◽  
2009 ◽  
Vol 60 (5) ◽  
pp. 644-649 ◽  
Author(s):  
Thomas F. Whayne
Keyword(s):  
Cardiovascular Risk ◽  
High Density Lipoprotein ◽  
Nicotinic Acid ◽  
Cholesteryl Ester Transfer Protein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
High Density Lipoproteins ◽  
Transfer Protein

High-density lipoproteins are regarded as “good guys” but not always. Situations involving high-density lipoproteins are discussed and medication results are considered. Clinicians usually consider high-density lipoprotein cholesterol. Nicotinic acid is the best available medication to elevate high-density lipoprotein cholesterol and this appears beneficial for cardiovascular risk. The major problem with nicotinic acid is that many patients do not tolerate the associated flushing. Laropiprant decreases this flushing and has an approval in Europe but not in the United States. The most potent medications for increasing high-density lipoprotein cholesterol are cholesteryl ester transfer protein inhibitors. The initial drug in this class, torcetrapib, was eliminated by excess cardiovascular problems. Two newer cholesteryl ester transfer protein inhibitors, R1658 and anacetrapib, initially appear promising. High-density lipoprotein cholesterol may play an important role in improving cardiovascular risk in the 60% of patients who do not receive cardiovascular mortality/morbidity benefit from low-density lipoproteins reduction by statins.

Abstract WMP70: Enhancement of Atherosclerosis Prediction by Interaction of Circulating mir-212 with Hemoglobin A1c, Lipoprotein(a), and High-density Lipoprotein Cholesterol

Stroke ◽  
2017 ◽  
Vol 48 (suppl_1) ◽  
Author(s):  
Hye Seon Jeong ◽  
Jeeyeon Kim ◽  
Seo Hyun Lee ◽  
Junha Hwang ◽  
Jong Wook Shin ◽  
...  
Keyword(s):  
Cardiovascular Risk ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Hemoglobin A1c ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Risk Markers ◽  
Lipoprotein A ◽  
Validation Population

Background and Objectives: The present study aimed to identify atherosclerosis-related circulating miRNAs and to evaluate their interaction with other cardiovascular risk markers to improve the prediction of atherosclerosis presence. Methods: We used miRNA profiling to identify atherosclerosis-related miRNAs using serum of 8 non-atherosclerotic and 7 severe atherosclerotic ischemic stroke patients. Expression of the target miRNAs identified was validated in 38 non-atherosclerotic and 37 atherosclerotic patients. Associations of the target miRNAs with other cardiovascular risk markers to predict atherosclerosis presence were analyzed using forward logistic regression analysis. Interactions of miRNAs with risk markers in the prediction of atherosclerosis presence were analyzed using accuracy and discrimination analysis. Results: miR-212, -30c, -372, -454, and, -744 were identified as atherosclerosis-related miRNAs. Only miR-212 showed a significant increase in expression in atherosclerotic patients of the validation population. Of various established markers tested, hemoglobin A1c, high-density lipoprotein cholesterol, and lipoprotein(a) were independently related with atherosclerosis presence in the validation population. miR-212 significantly increased the accuracy (three markers, 78.55%; three markers+miR-212, 84.6%) and area under the receiver operating characteristic curve (three markers, 0.8258; three markers+miR-212, 0.8646) of atherosclerosis prediction by the three existing markers. Conclusion: We identified circulating miR-212 as a novel marker of atherosclerosis. miR-212 synergistically enhanced the prediction of atherosclerosis-presence in combination with hemoglobin A1c, high-density lipoprotein cholesterol, and lipoprotein(a). Thus, miR-212 is expected to improve the prediction of atherosclerosis using peripheral blood of patients.

Sign in / Sign up

Export Citation Format

Share Document